• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Innoviva, Inc. - Common Stock (NQ:INVA)

    22.32 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 22.32
    Bid (Size) 16.53 (100)
    Ask (Size) 25.00 (200)
    Prev. Close 22.32
    Today's Range 22.32 - 22.32
    52wk Range 16.52 - 25.14
    Shares Outstanding 65,504,384
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    INNOVIVA INC (NASDAQ:INVA) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗
    Via Chartmill
    News headline image
    Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire

    Performance

    YTD
    +12.3%
    +12.3%
    1 Month
    +3.2%
    +3.2%
    3 Month
    +6.3%
    +6.3%
    6 Month
    +9.1%
    +9.1%
    1 Year
    +27.7%
    +27.7%

    More News

    Read More
    News headline image
    Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Innoviva, Inc.
    Via Business Wire
    Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    News headline image
    Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
    Via MarketBeat
    News headline image
    Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗
    Via Benzinga
    News headline image
    Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
    Via Chartmill
    News headline image
    U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
    From Innoviva, Inc.
    Via Business Wire
    News headline image
    Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
    From Innoviva, Inc.
    Via Business Wire
    News headline image
    Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
    From Innoviva, Inc.
    Via Business Wire
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗
    Via Chartmill
    News headline image
    Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    News headline image
    Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
    From Innoviva Specialty Therapeutics
    Via Business Wire
    News headline image
    Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
    From Innoviva Specialty Therapeutics
    Via Business Wire
    News headline image
    Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗
    Via Chartmill
    News headline image
    Innoviva to Participate in Upcoming Investor Conferences
    From Innoviva, Inc.
    Via Business Wire
    News headline image
    Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential ↗
    Via Chartmill
    News headline image
    Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
    From Innoviva Specialty Therapeutics, Inc.
    Via Business Wire
    News headline image
    Expert Outlook: Innoviva Through The Eyes Of 4 Analysts ↗
    Via Benzinga
    News headline image
    This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗
    Via Benzinga
    News headline image
    Innoviva (INVA) Q2 Sales Jump 64% ↗
    Via The Motley Fool
    News headline image
    Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
    From Innoviva, Inc.
    Via Business Wire
    News headline image
    This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
    Via Benzinga
    News headline image
    FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
    From Innoviva Specialty Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Innoviva, Inc. - Common Stock publicly traded?
    Yes, Innoviva, Inc. - Common Stock is publicly traded.
    What exchange does Innoviva, Inc. - Common Stock trade on?
    Innoviva, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Innoviva, Inc. - Common Stock?
    The ticker symbol for Innoviva, Inc. - Common Stock is INVA on the Nasdaq Stock Market
    What is the current price of Innoviva, Inc. - Common Stock?
    The current price of Innoviva, Inc. - Common Stock is 22.32
    When was Innoviva, Inc. - Common Stock last traded?
    The last trade of Innoviva, Inc. - Common Stock was at 03/09/26 04:00 PM ET
    What is the market capitalization of Innoviva, Inc. - Common Stock?
    The market capitalization of Innoviva, Inc. - Common Stock is 1.46B
    How many shares of Innoviva, Inc. - Common Stock are outstanding?
    Innoviva, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.